India · Delayed Price · Currency is INR Gland Pharma Statistics
Total Valuation
Gland Pharma has a market cap or net worth of INR 546.86 billion. The enterprise value is 514.96 billion.
| Market Cap | 546.86B |
| Enterprise Value | 514.96B |
Important Dates
The last earnings date was Friday, November 6, 2026.
| Earnings Date | Nov 6, 2026 |
| Ex-Dividend Date | Aug 11, 2026 |
Share Statistics
Gland Pharma has 164.97 million shares outstanding. The number of shares has increased by 0.19% in one year.
| Current Share Class | 164.97M |
| Shares Outstanding | 164.97M |
| Shares Change (YoY) | +0.19% |
| Shares Change (QoQ) | +0.06% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 36.79% |
| Float | 89.47M |
Valuation Ratios
The trailing PE ratio is 44.27 and the forward PE ratio is 36.24. Gland Pharma's PEG ratio is 1.41.
| PE Ratio | 44.27 |
| Forward PE | 36.24 |
| PS Ratio | 7.75 |
| PB Ratio | 5.12 |
| P/TBV Ratio | 5.32 |
| P/FCF Ratio | 111.63 |
| P/OCF Ratio | 52.54 |
| PEG Ratio | 1.41 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 27.43, with an EV/FCF ratio of 105.12.
| EV / Earnings | 41.67 |
| EV / Sales | 7.29 |
| EV / EBITDA | 27.43 |
| EV / EBIT | 35.46 |
| EV / FCF | 105.12 |
Financial Position
The company has a current ratio of 4.59, with a Debt / Equity ratio of 0.02.
| Current Ratio | 4.59 |
| Quick Ratio | 3.13 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.13 |
| Debt / FCF | 0.51 |
| Interest Coverage | 66.80 |
Financial Efficiency
Return on equity (ROE) is 12.21% and return on invested capital (ROIC) is 14.01%.
| Return on Equity (ROE) | 12.21% |
| Return on Assets (ROA) | 7.34% |
| Return on Invested Capital (ROIC) | 14.01% |
| Return on Capital Employed (ROCE) | 12.95% |
| Weighted Average Cost of Capital (WACC) | 7.11% |
| Revenue Per Employee | 16.30M |
| Profits Per Employee | 2.85M |
| Employee Count | 4,332 |
| Asset Turnover | 0.57 |
| Inventory Turnover | 1.58 |
Taxes
In the past 12 months, Gland Pharma has paid 4.98 billion in taxes.
| Income Tax | 4.98B |
| Effective Tax Rate | 28.72% |
Stock Price Statistics
The stock price has increased by +79.07% in the last 52 weeks. The beta is 0.52, so Gland Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.52 |
| 52-Week Price Change | +79.07% |
| 50-Day Moving Average | 3,002.97 |
| 200-Day Moving Average | 2,341.38 |
| Relative Strength Index (RSI) | 67.38 |
| Average Volume (20 Days) | 481,661 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Gland Pharma had revenue of INR 70.61 billion and earned 12.36 billion in profits. Earnings per share was 74.88.
| Revenue | 70.61B |
| Gross Profit | 41.88B |
| Operating Income | 14.52B |
| Pretax Income | 17.34B |
| Net Income | 12.36B |
| EBITDA | 18.77B |
| EBIT | 14.52B |
| Earnings Per Share (EPS) | 74.88 |
Balance Sheet
The company has 34.41 billion in cash and 2.51 billion in debt, with a net cash position of 31.90 billion or 193.37 per share.
| Cash & Cash Equivalents | 34.41B |
| Total Debt | 2.51B |
| Net Cash | 31.90B |
| Net Cash Per Share | 193.37 |
| Equity (Book Value) | 106.86B |
| Book Value Per Share | 647.56 |
| Working Capital | 61.58B |
Cash Flow
In the last 12 months, operating cash flow was 10.41 billion and capital expenditures -5.51 billion, giving a free cash flow of 4.90 billion.
| Operating Cash Flow | 10.41B |
| Capital Expenditures | -5.51B |
| Depreciation & Amortization | 4.25B |
| Net Borrowing | -662.33M |
| Free Cash Flow | 4.90B |
| FCF Per Share | 29.70 |
Margins
Gross margin is 59.32%, with operating and profit margins of 20.57% and 17.50%.
| Gross Margin | 59.32% |
| Operating Margin | 20.57% |
| Pretax Margin | 24.56% |
| Profit Margin | 17.50% |
| EBITDA Margin | 26.59% |
| EBIT Margin | 20.57% |
| FCF Margin | 6.94% |
Dividends & Yields
This stock pays an annual dividend of 20.00, which amounts to a dividend yield of 0.60%.
| Dividend Per Share | 20.00 |
| Dividend Yield | 0.60% |
| Dividend Growth (YoY) | 11.11% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 26.69% |
| FCF Payout Ratio | 61.03% |
| Buyback Yield | -0.19% |
| Shareholder Yield | 0.42% |
| Earnings Yield | 2.26% |
| FCF Yield | 0.90% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Analyst Forecast
The average price target for Gland Pharma is 3,249.00, which is -1.99% lower than the current price. The consensus rating is "Buy".
| Price Target | 3,249.00 |
| Price Target Difference | -1.99% |
| Analyst Consensus | Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | 15.80% |
| EPS Growth Forecast (3Y) | 23.39% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 7 |